FHTX — Foghorn Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1822462 ·
Last close
$6.87
Market Cap
$407.98M
52W High
$7.61
52W Low
$3.54
ADV30
284,410
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 16,072,000 | — | -8,805,000 | -7,191,000 | 203,393,000 | 68,080,000 | 284,434,000 |
| Mar 2026 | 3,267,000 | — | -21,573,000 | -19,875,000 | 222,167,000 | 87,663,000 | 298,575,000 |
| Dec 2025 | 9,247,000 | — | -19,596,000 | -21,664,000 | 198,103,000 | 80,876,000 | 306,603,000 |
| Sep 2025 | 8,153,000 | — | -18,501,000 | -15,849,000 | 204,962,000 | 89,334,000 | 294,620,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-84,241,000
Investing CF
$28,119,000
Financing CF
$50,380,000
CapEx
$-529,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.92
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-659,533,000
Inventory
—
Receivables
—
ST Investments
$99,502,000
EBIT TTM
$-68,475,000
Pretax Income TTM
$-64,579,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$36,739,000
EBITDA
$-66,353,000
Free Cash Flow
$-51,954,876
Enterprise Value
$283,497,120
Total Cash
$167,582,000
Total Debt
$43,102,000
Shares Out
59,385,315
Trailing EPS
$-0.99
Book Value
$-1.38
ROE
—
ROA
-19.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 30,909,000 | -82,107,000 | -74,283,000 | 198,103,000 | 306,603,000 | — | -86,099,000 |
| Dec 2024 | 22,602,000 | -100,285,000 | -86,620,000 | 283,982,000 | 329,510,000 | — | -100,406,000 |
| Dec 2023 | 34,155,000 | -107,906,000 | -98,426,000 | 285,916,000 | 363,106,000 | — | -118,106,000 |
| Dec 2022 | 19,228,000 | -117,137,000 | -108,882,000 | 404,883,000 | 404,771,000 | — | 193,612,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.03
Max Pain — expiry 2026-09-18
max pain strike: $5.00 · spot: $7.06 · call oi: 728 · put oi: 346Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARCT | Arcturus Therapeutics Holdings Inc. | $407.59M | $14.34 | — |
| ENTA | ENANTA PHARMACEUTICALS INC | $410.67M | $14.10 | — |
| PRLD | Prelude Therapeutics Inc | $420.01M | $6.47 | — |
| LRMR | Larimar Therapeutics, Inc. | $420.73M | $4.05 | — |
| CAPR | CAPRICOR THERAPEUTICS, INC. | $395.35M | $6.80 | — |
News headlines (Yahoo Finance, 1h cache)
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy
2026-08-14 16:00 · Yahoo
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?
2026-07-03 11:42 · Yahoo
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
2026-06-05 11:00 · Yahoo
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
2026-05-12 11:00 · Yahoo
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 12:50 · Yahoo
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
2026-05-07 11:00 · Yahoo
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
2026-05-06 14:00 · Yahoo
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
2026-04-21 20:05 · Yahoo
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
2026-04-09 11:00 · Yahoo
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade
2026-08-10 13:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.